Wiley

Ibrain Template

Write in a clean editor, then format for Ibrain in one click — DocuGuru applies the official Wiley template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.

About the Ibrain format

Ibrain is a peer-reviewed journal published by Wiley, covering Neuroinflammation and Neurodegeneration Mechanisms, Anesthesia and Neurotoxicity Research, Intensive Care Unit Cognitive Disorders.

PublisherWiley
Reference styleAuthor–year (Chicago)
Author–year — (Smith, 2023) in the text
Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Ibrain 12 (3): 45–58.

Formats any DOI in Ibrain style. No sign-up.

Publishes research inNeuroinflammation and Neurodegeneration Mechanisms Anesthesia and Neurotoxicity Research Intensive Care Unit Cognitive Disorders Spinal Cord Injury Research Anesthesia and Sedative Agents
ISSN2313-1934
Citation impact (2-yr)2.38
h-index16
i10-index38
Total citations1,348
Article processing charge$2,800
Open accessYes
Top institutions publishing hereZunyi Medical University
Journal websiteonlinelibrary.wiley.com
You getA submission-ready PDF and the editable LaTeX source — ready to submit.

Papers published in Ibrain per year

1
2006
4
2015
8
2016
12
2017
16
2018
16
2019
18
2020
48
2021
73
2022
58
2023
46
2024
30
2025

Citation impact of Ibrain by publication year

6
2006
4
2015
6
2016
7
2017
4
2018
8
2019
18
2020
172
2021
479
2022
401
2023
178
2024
30
2025

Citations each year’s papers have accumulated so far — the most recent years are still building up.

Most-cited papers in Ibrain

Basic information about memantine and its treatment of Alzheimer's disease and other clinical applications

Bin‐Can Tang, Ya‐Ting Wang, Jie Ren · 6 Jun 2023

Memantine is a noncompetitive moderate-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist. It has been used to treat Alzheimer's disease (AD) since 1989. In 2018, it became the second most commonly used drug for the treatment of dementia in the world. AD is nonreversible, and memantine can only relieve the symptoms of AD but not cure it.…

The role of microglia in Alzheimer's disease and progress of treatment

Yi‐Huan Guan, Ling‐Jing Zhang, Ling‐Jing Zhang et al. · 22 Feb 2022

Microglia are permanent immune cells of the central nervous system. Microglia play an important role in the pathological process of Alzheimer's disease (AD). They are mainly involved in the uptake and clearance of amyloid-β (Aβ), as well as the formation of neuroinflammation. We found that overactivated microglia increase Aβ and Tau, and Aβ and Tau…

Research advances in the clinical application of esketamine

Xiaoxi Zhang, Naixin Zhang, Dexing Liu et al. · 1 Mar 2022

Esketamine is dextrorotatory ketamine, which is an enantiomer of ketamine. Compared with ketamine, it has the advantages of a fast metabolism, fewer side effects, and strong pharmacological effects, so it is more suitable for clinical use. Esketamine has a powerful analgesic effect and has little effect on breathing. It has a wide range of applications…

Gold and silver nanoparticles in Alzheimer's and Parkinson's diagnostics and treatments

Edoardo Scarpa, Mariafrancesca Cascione, Anna Griego et al. · 14 Aug 2023

Neurodegenerative diseases (NDs) impose substantial medical and public health burdens on people worldwide and represent one of the major threats to human health. The prevalence of these age-dependent disorders is dramatically increasing over time, a process intrinsically related to a constantly rising percentage of the elderly population in recent years. Among all the NDs, Alzheimer's…

Global, regional, and national burdens of Alzheimer's disease and other forms of dementia in the elderly population from 1999 to 2019: A trend analysis based on the Global Burden of Disease Study 2019

Mengdan Su, Tianhong Wang, Congcong Zou et al. · 22 Sep 2024

Dementia represents a significant health issue, afflicting both patients and their families. To assess the global trends in the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of Alzheimer's disease (AD) and other dementias in the elderly population, the Global Burden of Disease Study (1999-2019) was used. The average annual percentage change (AAPC) was estimated…

Ibrain template — frequently asked questions

How do I write a paper in the Ibrain format?
In DocuGuru you write your manuscript in a normal editor — no LaTeX setup required — and select the Ibrain template. When you export, DocuGuru compiles the paper into the official Wiley format and hands you a submission-ready PDF along with the editable LaTeX source.
What reference style does Ibrain use?
Ibrain uses Author–year (Chicago) references, shown as author–year markers such as (Smith, 2023) in the text. DocuGuru formats every in-text citation and the reference list in this exact style automatically. A reference appears like this: Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Ibrain 12 (3): 45–58.
Do I need to know LaTeX to submit to Ibrain?
No. DocuGuru generates the USG LaTeX class and compiles the PDF for you in the background, so you get a Wiley-ready Ibrain document without writing any LaTeX. If you do want it, the LaTeX source is included in the export.
Can I import an existing draft into the Ibrain template?
Yes. Paste or upload your current manuscript — Word, LaTeX, Markdown, or plain text — and DocuGuru reflows it into the Ibrain format with correct headings, figures, tables, and author–year citations.
Who publishes Ibrain?
Ibrain is a multidisciplinary journal published by Wiley. DocuGuru's Ibrain template matches Wiley's official submission format.
Can I export a submission-ready Ibrain PDF?
Yes — DocuGuru produces a PDF built with the official Ibrain template (the USG class) that is ready to submit to Wiley, together with the matching LaTeX source files.
How much does the Ibrain template cost?
You can start writing in the Ibrain template for free. Exporting the final submission-ready Ibrain PDF and LaTeX source is part of DocuGuru's paid plans — see the app for current pricing.
Use the Ibrain template